WASHINGTON (dpa-AFX) - Boston Scientific Corp. (BSX) announced the global introduction of the Expect 19 Flex Endoscopic Ultrasound Aspiration Needle, used for acquiring tissue samples under Endoscopic Ultrasound or EUS guidance for cancer diagnosis in organs adjacent to the gastrointestinal tract. The Expect 19 Flex Needle is designed with a Nitinol construction for improved flexibility compared to existing EUS-Fine Needle Aspiration or FNA devices and a large diameter for expanded diagnostic capabilities. Endoscopic ultrasound is a non-surgical, less-invasive procedure that uses high-frequency sound waves to produce detailed images of the gastrointestinal tract and adjacent organs, including the pancreas, liver, bile duct and mediastinal space. To complement EUS, FNA is often used to collect tissue samples for cancer diagnosis. The company said data shows that EUS-FNA procedures are associated with improved survival rates for pancreatic cancer patients due to more informed, stage-appropriate disease management.
Copyright RTT News/dpa-AFX
